Funding to accelerate development of next-generation intravascular ultrasound platform and support FDA clearance for U.S. market launch
SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B financing with new investors Shangbay Capital and two undisclosed multinational strategics joining founding investor Vensana Capital. The funding will accelerate the development of the Company’s advanced IVUS technology designed to enhance vascular imaging and patient outcomes and support 510(k) FDA clearance ahead of U.S. market launch.
“We are proud to continue supporting Evident Vascular, which is at the forefront of innovation in intravascular imaging that has become the standard of care in peripheral vascular and complex coronary interventions,” said Cynthia Yee, Partner at Vensana Capital. “Evident’s next generation IVUS platform represents a transformative step forward in vascular care, offering clinicians powerful tools to enhance diagnosis and guide treatment consistent with clinical evidence and today’s medical guidelines1.”
Evident Vascular’s vision is to transform vascular imaging through innovations that expand the adoption of IVUS by increasing its utility and accessibility in clinical practice. The Company’s commitment to innovation is driven by a team of industry experts, whose leadership further bolsters Evident’s trajectory toward success.
“This significant investment underscores our investors’ confidence in Evident Vascular’s mission and technology while highlighting the vital role of intravascular imaging in optimizing patient outcomes, clinical decision-making and procedural success,” stated Howard Rosen, CEO and co-founder of Evident Vascular. “We will accelerate our progress toward FDA clearance and further the development of our AI-powered IVUS solution, which aims to set a new standard in vascular image guided therapy.”
About Evident Vascular
Evident Vascular, Inc., is developing an advanced intravascular ultrasound (IVUS) platform designed to optimize vascular imaging for peripheral and coronary interventions. With the integration of artificial intelligence, the platform enhances image interpretation, streamlines workflows, and drives improved clinical outcomes. Evident Vascular’s mission is to empower clinicians with cutting-edge tools that enable precision, efficiency, and superior patient care. For more information on Evident Vascular, visit the company’s website and follow us on LinkedIn.
About Vensana Capital
Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Founded in 2019, Vensana has approximately $1 billion in capital under management and is actively investing in development and commercial stage companies across the medtech sector, including medical devices, data science-oriented solutions, life science tools & diagnostics, and tech-enabled services. Vensana’s investment team has a history of successfully partnering with entrepreneurs behind industry-leading companies, including Artelon, Cameron Health, CardiAQ, Cartiva, CV Ingenuity, CVRx, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical. Learn more at www.vensanacap.com.
Evident Vascular™ and Evident™ are trademarks of Evident Vascular, Inc.
Vensana Capital® is a registered trademark of Vensana Capital Management, LLC.
This press release contains “forward-looking statements” concerning the development of Evident Vascular’s products, the benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Evident Vascular undertakes no obligation to update any forward-looking statements for any reason.
1 Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online February 27, 2025. doi:10.1161/CIR.0000000000001309
Contacts
Media inquiries: info@evidentvascular.com
